Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 14/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TPI1 | P60174 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.44 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.44 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19747601 | 0.92 | AR (0.51) | LMNAARENPP1PARP1PARP2 | |
| SCHEMBL30089699 | 0.92 | AR (0.51) | LMNAARENPP1PARP1PARP2 | |
| SCHEMBL29655130 | 0.87 | AR (0.52) | LMNAARENPP1PARP1PARP2 | |
| SCHEMBL19748384 | 0.87 | AR (0.52) | LMNAARENPP1PARP1PARP2 | |
| SCHEMBL21528284 | 0.87 | LMNA (0.55) | LMNAARENPP1PARP1PARP2 | |
| SCHEMBL29655172 | 0.87 | LMNA (0.55) | LMNAARENPP1PARP1PARP2 | |
| SCHEMBL29655280 | 0.85 | AR (0.49) | LMNAARENPP1PARP1PARP2 | |
| SCHEMBL19747595 | 0.85 | AR (0.49) | LMNAARENPP1PARP1PARP2 | |
| SCHEMBL19748896 | 0.84 | AR (0.51) | LMNAARENPP1PARP1PARP2 | |
| SCHEMBL29655126 | 0.84 | AR (0.51) | LMNAARENPP1PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | ATLASMEDX, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3475272-B1 | PHTHALAZINE DERIVATIVES AS INHIBITORS OF PARP1, PARP2 AND/OR TUBULIN USEFUL FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20220402894-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | ATLASMEDX, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11072600-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-27 | — | — | US | disclosed |
| US-10640493-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190352283-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | ATLASMEDX, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20190337928-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | ATLASMEDX, INC. | 2019-11-07 | — | — | US | disclosed |
| EP-3475272-A1 | PHTHALAZINE DERIVATIVES AS INHIBITORS OF PARP1, PARP2 AND/OR TUBULIN USEFUL FOR THE TREATMENT OF CANCER | The Regents of The University of California (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017223516-A1 | PHTHALAZINE DERIVATIVES AS INHIBITORS OF PARP1, PARP2 AND/OR TUBULIN USEFUL FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402894-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | PARP2, PARP12, PARP1 | LMNA 1010/4885AR 2031/4885ENPP1 1493/4885 |
| US-20190337928-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | PARP2, PARP12, PARP1 | LMNA 1010/4885AR 2031/4885ENPP1 1493/4885 |
| US-10640493-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | LMNA 1020/4885AR 1326/4885ENPP1 1334/4885 |
| US-11072600-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | LMNA 1010/4885AR 2031/4885ENPP1 1493/4885 |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | LMNA 1010/4885AR 2031/4885ENPP1 1493/4885 |
| US-20190352283-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | PARP2, PARP12, PARP1 | LMNA 1020/4885AR 1326/4885ENPP1 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.